Introduction
============

Despite many years of primary and clinical research aimed at curbing tumor growth, metastasis remains the main cause of mortality in cancer patients ([@b1-etm-04-06-1127]). During recent years, mounting evidence has shown that plasminogen activator inhibitor-1 (PAI-1), belonging to the urokinase plasminogen activation (uPA) system, plays an important role in signal transduction, cell adherence and cell migration, thus promoting invasion and metastasis ([@b2-etm-04-06-1127]). In addition, PAI-1 concentrations and mRNA levels in primary tumor tissues correlate with adverse patient outcome in multiple cancer types ([@b3-etm-04-06-1127]--[@b6-etm-04-06-1127]). Recently, the first level-of-evidence-1 (LOE-1) cancer biomarker, PAI-1, entered clinical practice in breast cancer management ([@b7-etm-04-06-1127]).

The PAI-1 gene is located on chromosome 7 and contains 8 introns and 9 exons ([@b8-etm-04-06-1127]). Gene variability may contribute to the level of PAI-1 biosynthesis. Among the variants of the PAI-1 gene, the PAI-1 4G/5G polymorphism (rs1799768) has been the most frequently studied. The 4G allele of 4G/5G insertion/deletion polymorphism located in the promoter region 675 bp upstream from the transcription start sequence of the PAI-1 gene is responsible for higher plasma PAI-1 levels, conditioning a clear hypofibrinolytic state ([@b9-etm-04-06-1127]). Several studies ([@b10-etm-04-06-1127],[@b11-etm-04-06-1127]) have shown that the 4G allele has greater activity than the 5G allele and that higher frequencies of the 4G allele are associated with elevated plasma levels of PAI-1.

To date, a number of molecular epidemiological studies have been performed to evaluate the association between PAI-1 promoter 4G/5G polymorphism and risks for different types of tumor, including breast cancer ([@b12-etm-04-06-1127]--[@b17-etm-04-06-1127]), colorectal cancer ([@b3-etm-04-06-1127],[@b18-etm-04-06-1127]--[@b20-etm-04-06-1127]), ovarian cancer ([@b21-etm-04-06-1127],[@b22-etm-04-06-1127]), oral cancer ([@b23-etm-04-06-1127],[@b24-etm-04-06-1127]), endometrial cancer ([@b25-etm-04-06-1127],[@b26-etm-04-06-1127]) and other cancers ([@b27-etm-04-06-1127],[@b28-etm-04-06-1127]), in diverse populations However, the observed associations of these studies were inconsistent and a single study may be insufficient to detect a possible small effect of the polymorphism on cancer, particularly when the sample size is relatively small. Hence, we performed a meta-analysis of all eligible studies to derive a more precise estimation of the association of PAI-1 promoter 4G/5G polymorphism with cancer risk. To our knowledge, no meta-analysis concerning the influence of PAI-1 4G/5G polymorphism on cancer risk has been published in the literature.

Materials and methods
=====================

Publication search
------------------

We carried out a search in PubMed, Scopus, Web of Science and Chinese National Knowledge Infrastructure (CNKI) databases with a combination of the following keywords: 'plasminogen activator inhibitor-1', 'PAI-1', 'SERPINE1', 'polymorphism', 'variation', 'variant', 'carcinoma', 'tumor' and 'cancer' (the last search was updated on 10th February 2012). We evaluated potentially relevant publications by examining their titles and abstracts. All studies with full text matching the eligible criteria were retrieved. Additional relevant studies were identified by a manual search of the references of retrieved articles and reviews.

Inclusion criteria
------------------

Studies included in this meta-analysis met the following criteria: a) evaluation of the link between PAI-1 promoter 4G/5G polymorphism and cancer risk, b) a case-control design, c) contained sufficient published data for estimating odds ratios (ORs) and 95% confidence intervals (CIs).

Quality assessment
------------------

The quality of each study was assessed independently by two reviewers who used the Newcastle-Ottawa Scale (NOS) ([@b29-etm-04-06-1127]). The NOS consists of three parameters of quality: selection, comparability, and exposure (case-control studies) or outcome (cohort studies). Scores ranged from 0 stars (worst) to 9 stars (best). Studies with a score ≥7 stars were considered to be of high quality. Any discrepancies were settled by a joint re-evaluation of the original article with a third reviewer.

Data extraction
---------------

Information was extracted independently by two reviewers according to the inclusion criteria. Any disagreement was settled by consensus among the two. For each study, the following characteristics were collected: the first author's last name, year of publication, country of origin, ethnicity, numbers of genotyped cases and controls, source of control groups and genotyping methods. Different ethnic descents were categorized as Caucasian, Asian and mixed, which included more than one ethnic descent. We also contacted study authors for any missing data.

When the source of controls was not clearly defined in the paper, it was defined 'not specified' to be conservative. The ethnicity of each study population was defined as the ethnic group of ≥90% of the study subjects. When the paper did not specify the ethnicity of the study population, it was hypothesized based on the most frequent ethnic group in the study country.

Statistical methods
-------------------

Crude ORs together with their corresponding 95% CIs were used to calculate and assess the strength of association between PAI-1 promoter 4G/5G polymorphism and cancer risk. We first estimated cancer risk associated with PAI-1 promoter 4G/5G polymorphism by 4G/4G and 4G/5G genotypes compared with the 5G/5G (co-dominant model) and then evaluated 4G/4G+4G/5G vs. 5G/5G, and 4G/4G vs. 4G/5G+5G/5G, assuming the dominant and recessive effects of the variant 4G allele, respectively. The departure of frequencies from those expected under Hardy-Weinberg equilibrium (HWE) was assessed by Chi-square goodness-of-fit tests in controls. Stratified analyses were also performed by cancer type (if a cancer type was represented by only a single study, it was combined with the 'other cancers' group) and ethnicity.

For the heterogeneity test, a random-effect model (the DerSimonian and Laird method) ([@b30-etm-04-06-1127]) was used when P\<0.05, otherwise a fixed-effect model (the Mantel-Haenszel method) ([@b31-etm-04-06-1127]) was used. In the random-effect model, we incorporated the random variation within the studies and the variation among the different studies, and in the fixed-effect model, we assumed that all studies came from a common population and the effect size was not significantly different among the different studies.

With regard to sensitive analyses, the influence of each study in the pooled OR was examined by repeating meta-analyses while omitting each study one at a time. We performed visual inspection of funnel plots to examine the underlying publication bias, and also used Egger's weighted regression method to calculate P for bias ([@b32-etm-04-06-1127]). All statistical analyses were performed with STATA 11.0 (StataCorp, TX, USA), using two-sided P-values.

Results
=======

Summary statistics
------------------

We identified 21 articles ([@b3-etm-04-06-1127],[@b12-etm-04-06-1127]--[@b28-etm-04-06-1127],[@b33-etm-04-06-1127]--[@b35-etm-04-06-1127]) which we used to evaluate the association of PAI-1 promoter 4G/5G polymorphism with risk of cancer. The study characteristics are summarized in [Table I](#t1-etm-04-06-1127){ref-type="table"}. Among the 21 eligible case-control studies, which included 8,415 cases and 9,208 controls, there were 7 breast cancer studies, 4 colorectal cancer studies, 3 ovarian cancer studies, 2 oral cancer studies, 2 endometrial cancer studies, and the others were categorized into the 'other cancer' group. Continental origin populations among these studies were as follows: 13 studies with Caucasian subjects, 7 studies with Asian subjects, and one study with more than one ethnicity (classified as mixed). Cancers were confirmed histologically in most studies. Diverse genotyping methods were used, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP), TaqMan, sequencing, minisequencing, real-time PCR and matrix-assisted laser desorption/ionizing time-of-flight mass spectrometry (MALDI/TOF). The distribution of genotypes in the controls was consistent with HWE in all but one of the studies ([@b35-etm-04-06-1127]).

Quality assessment results
--------------------------

The NOS results showed that 81.0% of the studies were of high quality (NOS score \>6), with an average NOS score of 7.6, which indicated that the methodological quality was generally good. We defined studies that scored ≥7 as having high methodological quality, and we judged 4 ([@b21-etm-04-06-1127],[@b22-etm-04-06-1127],[@b26-etm-04-06-1127],[@b35-etm-04-06-1127]) of the 21 studies to be of low quality (score of 6) primarily due to the absence of a definition of controls and a lack of a description of comparability between cases and controls.

Quantitative synthesis
----------------------

The overall OR with its 95% CI revealed a statistical association between the PAI-1 promoter 4G/5G polymorphism and the risk of cancer (4G/4G vs. 5G/5G: OR=1.25, 95% CI=1.07--1.47, P~heterogeneity~=0.001; 4G/4G vs. 4G/5G+5G/5G: OR=1.10, 95% CI=1.03--1.17, P~heterogeneity~=0.194; 4G/4G+4G/5G vs. 5G/5G: OR=1.17, 95% CI=1.01--1.35, P~heterogeneity~=0.041; [Figs. 1](#f1-etm-04-06-1127){ref-type="fig"} and [2](#f2-etm-04-06-1127){ref-type="fig"}). In the subgroup analysis by ethnicity, statistically significant elevated cancer risks were found among Caucasians (4G/4G vs. 5G/5G: OR=1.39, 95% CI=1.12--1.74, P~heterogeneity~=0.001; 4G/4G vs. 4G/5G+5G/5G: OR=1.12, 95% CI=1.04--1.21, P~heterogeneity~=0.136; 4G/4G+4G/5G vs. 5G/5G: OR=1.28, 95% CI=1.04--1.57, P~heterogeneity~=0.000; [Fig. 1](#f1-etm-04-06-1127){ref-type="fig"}). Moreover, when stratifying by cancer type, significantly increased cancer risks were observed for endometrial cancer in all comparison models (4G/4G vs. 5G/5G: OR=2.23, 95% CI=1.46--3.42, P~heterogeneity~=0.951; 4G/5G vs. 5G/5G: OR=1.56, 95% CI=1.08--2.25, P~heterogeneity~=0.830; 4G/4G vs. 4G/5G+5G/5G: OR=1.64, 95% CI=1.19--2.27, P~heterogeneity~=0.866; 4G/4G+4G/5G vs. 5G/5G: OR=1.74, 95% CI=1.23--2.47, P~heterogeneity~=0.979; [Fig. 2](#f2-etm-04-06-1127){ref-type="fig"}). The details are listed in [Table II](#t2-etm-04-06-1127){ref-type="table"}.

Sensitivity analysis
--------------------

In the sensitivity analysis ([Fig. 3](#f3-etm-04-06-1127){ref-type="fig"}), the influence of each study on the pooled OR was examined by repeating the meta-analysis while omitting each study, one at a time. This procedure demonstrated that our results were reliable and robust. In addition, when excluding the studies that were not in HWE, the estimated pooled OR still did not change at all.

Publication bias
----------------

Publication bias was assessed by visual inspection of funnel plots in which the standard error of the log (OR) of each study was plotted against its log (OR). An asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test, a linear regression approach for measuring funnel plot asymmetry on the natural logarithm scale of the OR. The significance of the intercept was determined by the t-test (P\<0.05 was considered representative of statistically significant publication bias) ([@b32-etm-04-06-1127]). As a result, publication bias was identified in certain comparisons (4G/4G vs. 5G/5G, 4G/5G vs. 5G/5G, and 4G/4G+4G/5G vs. 5G/5G).

Discussion
==========

The promoter 4G/5G polymorphism is the most well-characterized PAI-1 polymorphism, but the reported associations with cancer risk among studies are inconsistent. Our present meta-analysis, incorporating 21 case-control studies (8,415 cases and 9,208 controls), suggests that the promoter 4G/5G polymorphism is significantly associated with increased cancer risk, particularly in Caucasians.

How a promoter 4G/5G polymorphism increases the risk of developing cancer is yet to be established; however, it is known that the transcription of the PAI-1 gene is affected by the presence of a guanosine insertion (5G)/deletion (4G) polymorphism at the promoter region ([@b13-etm-04-06-1127],[@b36-etm-04-06-1127]). Both 4G and 5G alleles bind a transcriptional activator, whereas the 5G allele also binds a repressor ([@b36-etm-04-06-1127]). Hence, the presence of 4G/4G homozygotes enhances transcription to increase plasma PAI-1 levels, whereas 5G/5G homozygotes are associated with lower levels of the inhibitor ([@b13-etm-04-06-1127],[@b36-etm-04-06-1127]). High plasma PAI-1 concentrations have been reported to be a predictive indicator of poor prognosis and shorter survival of patients with cancer ([@b4-etm-04-06-1127]--[@b6-etm-04-06-1127],[@b37-etm-04-06-1127]). The PAI-1 4G/5G polymorphism has also been found to be located within the functional binding sites for the transcription factors Smad and NF-κB, which mediate the effects of two known inducers of PAI-1 expression, transforming growth factor-β (TGF-β) and tissue necrosis factor-α (TNF-α), respectively ([@b38-etm-04-06-1127],[@b39-etm-04-06-1127]).

Since tumor origin may influence the results of the meta-analyses, we performed subgroup analyses by cancer type. The association of the PAI-1 promoter 4G/5G polymorphism with increased risk of cancer in this meta-analysis was significant in the endometrial cancer subgroup. In addition to the above reasons, the presence of the 4G allele results in a higher PAI-1 transcription response to cytokines or growth factors than the 5G allele, so the 4G/5G polymorphism may influence tissue PAI-1 levels in endometrial cancer patients through the action of cytokines released by tumor cells ([@b25-etm-04-06-1127]). However, since only two independent studies with limited sample size were included in this meta-analysis, further studies with a larger number of patients are needed to explore the clinical significance of the PAI-1 4G/5G polymorphism in endometrial cancer.

Due to differences in the underlying genetic backgrounds and/or environmental and social factors of the different populations studied, the incidence of gene polymorphisms varies substantially between different racial or ethnic populations. In this meta-analysis, when stratifying by ethnicity we found that the association between PAI-1 promoter 4G/5G polymorphism and increased risk of cancer was significant only in Caucasians, not in the Asian population. As a multi-factorial disease, the factors causing cancer vary in different populations. Although the reasons for this difference remain controversial, there are several studies showing that it depends on a combination of differences in polymorphism distributions with nongenetic factors. Therefore, the functional difference of this polymorphism of PAI-1 in Caucasians and Asians may result from interactions with environmental and social factors. In addition, considering the multistage character of cancer, genetic factors may play a role at specific stages only, which may vary between populations. Therefore, larger-scale studies and combined analysis are warranted to further confirm the effect of ethnic difference in this polymorphism on cancer risks. These studies should be stratified by ethnicity, differentiated by the stage of carcinogenesis and include an assessment of interactions with environmental factors.

Additionally, heterogeneity may influence the results of meta-analyses. Evident heterogeneity between studies was observed in overall comparisons and also in certain subgroup analyses. Through the subgroup analysis, we found that the source of heterogeneity was from types of cancer and ethnicity, suggesting that tumor site and population play an important role for the same polymorphism.

When interpreting the results, the following limitations of the study should be considered. First, only published articles were included in this study. Although we conducted a thorough and comprehensive search and also contacted study authors for missing data ([@b13-etm-04-06-1127]), publication bias could not be completely avoided. To evaluate the results, Egger's test was performed. The results show that key publication bias may be present in this meta-analysis as there was some uncertainty with the P-value being less than 0.05 in Egger's test, hence some results should be interpreted cautiously. Secondly, lack of the original data of the reviewed studies limited our further evaluation of potential interactions, since the interactions between gene-to-gene, gene-to-environment and even different polymorphic loci of the same gene may modulate cancer risk.

Our results suggest that the PAI-1 promoter 4G/5G polymorphism is a potential clinical genetic marker contributing to cancer susceptibility. Whether it could be applied to genotyping for clinical assessment requires large-scale population studies among different ethnicities and regions.
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###### 

Characteristics of populations and cancer types of studies included in the meta-analysis.

  Study (year)             Country of origin   Ethnicity   Source of control   Cancer type      Genotyping method   Cases (no.)   Controls (no.)   HWE
  ------------------------ ------------------- ----------- ------------------- ---------------- ------------------- ------------- ---------------- -----
  Türkmen 1997             German              Caucasian   ns                  Ovarian          PCR-RFLP            22            23               Yes
  Blasiak 2000             Poland              Caucasian   ns                  Breast           PCR-SSCP            100           106              Yes
  Loktionov 2003           UK                  Caucasian   PCC                 colorectal       PCR-SSCP            206           355              Yes
  Bi 2004                  China               Asian       PCC                 Breast           PCR-SSCP            53            146              No
  Zhou 2005                China               Asian       HCC                 Ovarian          PCR-SSCP            52            30               Yes
  Eroglu 2006              Turkey              Caucasian   ns                  Breast           PCR-SSCP            34            90               Yes
  Castellò 2006            Spain               Caucasian   PCC                 Breast           PCR-SSCP            104           104              Yes
  Sternlicht 2006          USA                 Caucasian   PCC                 Breast           Minisequencing      2,539         1,832            Yes
  Vairaktaris 2006         Greece              Caucasian   PCC                 Oral             PCR-RFLP            104           106              Yes
  Eroglu 2007              Turkey              Caucasian   ns                  Mixed            PCR--SSCP           125           180              Yes
  Försti 2007              German              Caucasian   PCC                 Colorectal       Taqman              304           581              Yes
  Woo 2007                 Korea               Asian       ns                  Colorectal       PCR-RFLP            185           304              Yes
  Lei 2008                 German              Caucasian   PCC                 Breast           Taqman              959           952              Yes
  Bentov 2009              Canada              Mixed       HCC                 Ovarian          MALDI-TOF           775           889              Yes
  Palmirotta 2009          Italy               Caucasian   PCC                 Breast           Sequencing          99            50               Yes
  Ju 2010                  Korea               Asian       PCC                 Gastric          MALDI-TOF           252           406              Yes
  Weng 2010                Taiwan              Asian       HCC                 Hepatocellular   PCR-RFLP            102           344              Yes
  Gilabert-Estelles 2011   Spain               Caucasian   PCC                 Endometrial      Real-time PCR       212           211              Yes
  Su 2011                  Taiwan              Asian       HCC                 Endometrial      PCR-RFLP            134           302              Yes
  Vossen 2011              Netherlands         Caucasian   PCC                 Colorectal       Taqman              1,801         1,853            Yes
  Weng 2011                Taiwan              Asian       HCC                 Oral             PCR-RFLP            253           344              Yes

HCC, hospital-based case-control; PCC, population-based case-control; ns, not specified (source of controls was not clearly defined); PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP, single-strand conformation polymorphism analysis of polymerase chain reaction products; MALDI-TOF, matrix-assisted laser desorption/ionizing time-of-flight mass spectrometry; HWE, Hardy-Weinberg equilibrium.

###### 

Stratified analyses of the plasminogen activator inhibitor1 (PAI-1) 4G/5G polymorphism and cancer risk.

                                   4G/4G vs. 5G/5G         4G/5G vs. 5G/5G   Dominant model          Recessive model                                                           
  --------------- ---------------- ----------------------- ----------------- ----------------------- ----------------- ----------------------- ------- ----------------------- -------
  Total           21 (8415/9208)   **1.25 (1.07--1.47)**   0.001             1.12(0.97--1.30)        0.002             **1.17 (1.01--1.35)**   0.041   **1.10 (1.03--1.17)**   0.194
  Cancer type                                                                                                                                                                  
    Breast        7 (3888/3280)    1.13 (0.99--1.30)       0.120             1.15 (0.86--1.54)       0.032             1.19 (0.91--1.56)       0.272   1.06 (0.96--1.17)       0.456
    Colorectal    4 (2496/3093)    1.04 (0.89--1.21)       0.864             0.88 (0.76--1.01)       0.852             0.93 (0.82--1.07)       0.941   **1.13 (1.01--1.27)**   0.524
    Oral          2 (357/450)      1.94 (0.54--6.91)       0.006             1.67 (0.63--4.41)       0.028             1.80 (0.60--5.45)       0.008   1.20 (0.88--1.64)       0.078
    Endometrial   2 (346/513)      **2.23 (1.46--3.42)**   0.951             **1.56 (1.08--2.25)**   0.830             **1.74 (1.23--2.47)**   0.979   **1.64 (1.19--2.27)**   0.866
    Ovarian       3 (849/942)      0.97 (0.75--1.27)       0.999             0.95 (0.75--1.21)       0.469             0.96 (0.77--1.20)       0.746   1.00 (0.81--1.23)       0.519
    Other         3 (479/930)      1.46 (0.58--3.63)       0.002             1.42 (0.71--2.83)       0.013             1.43 (0.66--3.09)       0.003   1.02 (0.80--1.29)       0.102
  Ethnicity                                                                                                                                                                    
    Caucasian     13 (6609/6443)   **1.39 (1.12--1.74)**   0.001             **1.21 (0.98--1.50)**   0.000             **1.28 (1.04--1.57)**   0.000   **1.12 (1.04--1.21)**   0.136
    Asian         7 (1031/1876)    1.10 (0.88--1.38)       0.171             1.07 (0.87--1.32)       0.718             1.08 (0.89--1.32)       0.393   1.05 (0.89--1.25)       0.330

OR, odds ratio; CI, confidence interval.

P-value of Q-test for heterogeneity. Random-effects model was used when P-value for heterogeneity test \<0.05; otherwise, fixed-effects model was used. Bold values indicate a significant difference.
